Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

On Thursday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $122.41 which represents a slight increase of $4.42 or 3.75% from the prior close of $117.99. The stock opened ...

Analyst Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $177.83, a high ...

The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...

COLUMN: ‘Among many heroes in the broad societal programme to imagine and construct new futures for South Africans, as ...

Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $120.4 which represents a slight increase of $1.64 or 1.38% from the prior close of $118.76. The stock opened at $119.91 ...

innovation capabilities, and adaptability to shifting economic landscapes. Name Revenue Growth Earnings Growth Growth Rating Clinuvel Pharmaceuticals 22.32% 27.42% Sarepta Therapeutics 23.67% ...

Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

Originally published in Quest Diagnostics' 2023 Corporate Responsibility Report We continued to grow access to and ...

Check the time stamp on this data. Updated AI-Generated Signals for Sarepta Therapeutics Inc. (SRPT) available here: SRPT.